Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.
Por:
Esposito S, Stefanelli P, Fry NK, Fedele G, He Q, Paterson P, Tan T, Knuf M, Rodrigo C, Weil Olivier C, Flanagan KL, Hung I, Lutsar I, Edwards K, O'Ryan M and Principi N
Publicada:
3 jul 2019
Ahead of Print:
3 jul 2019
Resumen:
Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated B. pertussis components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence.
Filiaciones:
Esposito S:
Department of Surgical and Biomedical Sciences, Paediatric Clinic, Università degli Studi di Perugia, Perugia, Italy
Stefanelli P:
Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
Fry NK:
Immunisation and Countermeasures Division, Public Health England-National Infection Service, London, United Kingdom
Fedele G:
Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
He Q:
Institute of Biomedicine, University of Turku, Turku, Finland
Department of Medical Microbiology, Capital Medical University, Beijing, China
Paterson P:
Department of Infectious Disease Epidemiology, The Vaccine Confidence Project TM, London School of Hygiene & Tropical Medicine, London, United Kingdom
Tan T:
Division of Pediatric Infectious Diseases, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, United States
Knuf M:
Children's Hospital, Helios HSk, Wiesbaden, Germany
Department of Pediatrics, University Medicine, Mainz, Germany
:
Department of Pediatrics, Vall d'Hebron University Hospital, Barcelona, Spain
School of Medicine-Germans Trias i Pujol University Hospita, Universidad Autónoma de Barcelona, Barcelona, Spain
Weil Olivier C:
Retired, Neuilly-sur-Seine, France
Flanagan KL:
School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia
School of Health and Biomedical Science, RMIT University, Melbourne, VIC, Australia
Department of Immunology and Pathology, Monash University, Melbourne, VIC, Australia
Hung I:
Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Lutsar I:
Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
Edwards K:
Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, United States
O'Ryan M:
Microbiology and Mycology Program, Faculty of Medicine, Institute of Immunology and Immunotherapy, University of Chile, Santiago, Chile
Principi N:
Retired, Milan, Italy
|